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S186 Oral Presentationsrespectively. In multivariate model, 1-year and long-term OS were
better in boys (p 5 0.024) and patients receiving a pre-cryo TNC
. 2.5x107/kg (p 5 0.0002). In patients with malignancies, higher
HLA-B mismatching (2 vs. 0 or 1) and in non-malignancy patients,
higher HLA-DRB1 mismatching (1 vs. 0) led to worse OS (table).
HLA-A mismatching (1 vs. 0) had no impact. OS in minority and
Caucasian patients were similar. Probability of malignancy relapse
at 5 yrs was 10.1%(95%CI 5.8%-14.4%).
Table 1. Overall Survival: Significant Factors in Multivariate
Analysis
All patients Hazard Ratio (95% CI) p - valuePre-Cryo TNC < or 5 2.5x10e7/kg 1.000
Pre-Cryo TNC > 2.5x10e7/kg 0.415 (0.26-0.66) 0.0002
Recipient Sex: Male 1.000
Recipient Sex: Female 1.431 (1.05-1.95) 0.0241
Malignant Diagnoses
Recipient CMV Negative 1.000
Recipient CMV Positive 1.482 (1.02-2.16) 0.04
0 or 1 HLA-B Mismatch 1.000
2 HLA-B Mismatches 2.832 (1.24-6.49) 0.0139
Non-Malignant Diagnoses
Pre-Cryo TNC < or 5 8.6x10e7/kg 1.000
Pre-Cryo TNC > 8.6x10e7/kg 0.570 (0.34-0.96) 0.0354
No HLA-DRB1 Mismatch 1.000
1 HLA-DRB1 Mismatch 1.732 (1.02-2.93) 0.0412CONCLUSIONS: 4/6 matched UCBT is effective and carries low
probabilities of graft failure, acute GVHD (III-IV) and chronic
GVHD in children and young patients. These outcomes are similar
to those reported with better matched UCB grafts and support the
use of 4/6 UCBT for patients lacking other donors. HLA-A, -B
and -DRB1 mismatching has differential outcome on OS. Further
studies will help in utilizing these differences to optimize CBU
selection.88
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Background:CAYA with ALL or AML in third complete remission
(CR3), refractory relapse (RR) or induction failure (IF) continue to
have extremely poor prognosis,\ 20% EFS (Gaynon, BJH, 2005,
Wells et al, JCO, 2003). CLO is an inhibitor of DNA polymerase
and ribonucleotide reductase and has demonstrated activity in
CAYAwith relapsed ALL/AML (Jeha et al., JCO, 2006, 2009). Stud-
ies suggest synergy with cytarabine (Faderl et al, Blood, 2005). CLO
with cytarabine has shown greater rates of CR than CLO alone in
adults with AML and in CAYA with relapsed ALL/ AML (Faderl
et al, Blood, 2006, 2008; Cooper et al, ASH, 2009).We sought to de-
termine maximum tolerated dose (MTD) or tolerable dose of CLO
and assess the safety, progression-free survival (PFS) and overall sur-
vival (OS) of CLO, cytarabine and TBI followed by AlloSCT in
CAYA with poor-risk ALL/ AML.
Methods: This is a multi-center phase I/II trial of novel condition-
ing regimen of CLO (dose escalation: 40mg/m2 [n 5 3], 46 mg/m2
[n 5 3], 52 mg/m2 [n 5 8]) x5d, sequential (4 hrs later) cytarabine
1000 mg/m2 x6d and TBI (1200cGy) followed by AlloSCT from
matched related or unrelated donors in CAYA with ALL/AML in
CR3, RR or IF. Pts with unrelated grafts received R-ATG.GVHDprophylaxis consisted of tacrolimus andMMF (Bhatia/Cairo
et al., BBMT, 2009). Kaplan-Meier method was used to determine
the probabilities of engraftment, GVHD, PFS and OS.
Results: 14 pts, median age: 10.6 yrs (5-18); M:F: 10:4, ALL/AML:
11:3 (9 CR3, 2 RR, 3 IF), 6 related donors, 8 unrelated donors (5
BM/PBSCs, 3 UCB). Median TNC and CD34 dose was 5.04x108/
kg and 5.04x106/kg for BM/PBSCs and 4.0x107/kg and 1.8x105/
kg for UCB. Probabilities of neutrophil and platelet engraftment
and grade II-IV aGVHD were 100%, 91.7% and 51.8%, respec-
tively. All achieved 100% whole blood donor chimerism by day 30.
Day 100 TRM was 0%. CLO dose was tolerable at 52mg/m2/
d x5d and is being used in the phase II setting. No serious adverse
events related to CLO were observed. 2 pts experienced progressive
disease at days 90 and 126. 10 pts are alive in continuous CR at me-
dian 171 days (42-834). Probabilities of 1-yr PFS and OS are 60.2%
(CI95: 24-83%) and 54.0% (CI95: 18-80%), respectively.
Conclusions: Preliminary results suggest this regimen followed by
AlloSCT is safe and well tolerated in CAYA with poor-risk ALL/
AML with CLO dose of 52 mg/m2. Very early results are encourag-
ing with respect to low risk of early leukemic relapse with this
conditioning regimen.89
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Background:We analyzed the outcome of 18 consecutive-children
who receivedmatched unrelated donor (MUD) haematopoietic stem
cell transplantation (HCT) for idiopathic severe aplastic anaemia
(SAA) using an Alemtuzumab non-total body irradiation (TBI) based
conditioning regime.
Design and Methods: We conducted a multicentre retrospective
analysis to determine the efficacy of non-TBI, Alemtuzumab-based
conditioning regimens for HCT in idiopathic SAA. The outcomes
analysed were event free survival (EFS), overall survival (OS),
graft-versus-host-disease (GVHD) and viral reactivations.
Results: The median age transplantation was 14.3 years (range 0.7-
19 years). Fourteen of the 18 patients had failed to respond to prior
immunosuppressive therapy. Analysis of 18 patients who received 10
antigen (HLA-A,-B,-C,-DRB1,-DQB1) MUD HCT for idiopathic
SAA between 1999 and 2007 showed an EFS and OS of 100% at
a median follow-up of 3.7 years (range 2.5-10.83 years). Nine of
the 18 patients were full donor chimerae and the other 9 were stable
mixed chimerae (median donor chimerism 100 %; range 95-100 %).
All patients have normal neutrophil and platelets counts and are
transfusion independent. There were no cases of severe acute or ex-
tensive chronic GVHD. Eleven patients remained free of acute
GVHD, 6 developed grade I and only a single patient developed
grade II GVHD (cumulative incidence of grade I-II GVHD 38.8
%). No patient developed grade III-IV acute GVHD. Two patients
developed limited chronic GVHD of the skin (cumulative incidence
of limited chronic GVHD 11.1 %) and no patients developed exten-
sive chronic GVHD.There was a low rate of viral/bacterial morbid-
ity requiring treatment (adenoviral reactivation responding to
cidofovir [1], CMV reactivation responding to donor lymphocyte
infusion [1] and MRSA abscess[1]). There were no cases of EBV
post-transplant lymphoproliferative disease .
Conclusion: These data suggest that Alemtuzumab is sufficiently
immunosuppressive to permit engraftment following MUD HCT
in SAA whilst minimising toxicity and avoiding serious GVHD.
This approach avoids the potential concerns of late carcinogenesis
which accompany the use of TBI in this disease. In the absence of
a matched sibling donor, our data suggests that MUD HCT could
be considered as first line therapy before immune suppression for
Oral Presentations S187acquired SAA in children or young adults if a fullymatched unrelated
donor can be identified.90
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Wehave shown that Sleeping Beauty transposon/transposase can be
harnessed to stably express a CD19-specific chimeric antigen recep-
tor (CD19RCAR) to reprogram T cell specificity to B-cell tumors
independent of human leukocyte antigens (HLA), a technology
that is currently being evaluated clinically (IND#14193). However,
the time required tomanufacture patient-specific T cells to sufficient
numbers ex vivo can be incompatible with the window of opportunity
to treat patients with rapidly-progressing malignancies. An alterna-
tive approach is to prepare allogeneic T cells as third party effector
cells for infusion on demand. However, immune-mediated rejection
by recipient T cells recognizing disparate HLA and graft-versus-
host-disease mediated by the endogenous abT-cell receptor
(TCR) on the infused T cells may compromise this alternative ap-
proach to adoptive immunotherapy. To this end, we investigated
whether HLA and TCR expression can be eliminated in T cells by
designed zinc-finger nucleases (ZFNs). ZFNs are chimeric endonu-
cleases comprised of a zinc finger DNA binding domain designed to
bind a specific DNA sequence fused to the cleavage domain of Fok I
endonuclease. The introduction of a double strand break (DSB) at an
intended target site requires the design of two ZFNs that bind in
a specific spatial orientation to allow dimerization on DNA. Cellular
repair of DSB by error-prone non-homologous end joining results in
the permanent disruption of target gene expression. For an initial
proof-of-concept we designed ZFN pairs targeting the HLA-A lo-
cus. Since only transient expression of ZFNs is needed to perma-
nently disrupt a target gene, we tested the electro-transfer of in
vitro-transcribed ZFN mRNA in primary T cells. We show that ad-
ministration of the mRNA encoding the ZFNs targeting HLA-A re-
sulted in over 40%HLA-A negative primary T cells, which could be
readily enriched by paramagnetic bead separation to obtain a pool of
. 90% HLA-Anull T cells. By using the same approach, we tested
ZFN pairs targeting the TCRa or TCRb locus, resulting in a highly
enriched ab TCRnull cell population (. 90% ab TCRnull). Impor-
tantly, both sets of ZFNs were shown to successfully modify
CD19RCAR T cells, resulting in the efficient elimination of HLA-
A or ab TCR expression from CAR1 T cells which maintain redir-
ected specificity for CD19. These data support the potential for
allogeneic CD19-specific T cells as ‘‘off-the-shelf’’ biologics that
can be infused on demand as ‘‘drugs’’.91
INVERSE CORRELATION BETWEEN BMI AND TIME-TO-ENGRAFTMENT
AFTER PEDIATRIC HSCT: IMPLICATIONS FOR THE ROLE OF ADIPOCYTES
IN HEMATOPOIETIC STEM AND PROGENITOR CELL (HSPC) FUNCTION
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Recent studies have shown that adipocytes directly negatively reg-
ulate hematopoietic stem cell (HSC) function. It has also been shown
that visceral adiposity correlates with bone marrow fat content and
therefore increased adipocyte-HSC interaction, which may link
high body mass index (BMI) with increased negative regulation of
HSC function. Clinically, this has significant implications for stem
cell transplant patients, particularly as Americans in general and
the pediatric population in particular becomes more obese.
Many studies investigating the relationship between BMI and
transplant mortality have been done; the results of these studies are
somewhat contradictory. Additionally, interpretation of these stud-ies is complicated by the fact that transplant outcome is an endpoint
significantly downstream of HSC function, and is influenced by
many other factors affected by obesity.We sought to address directly
the issue of HSC function as influenced by adiposity, using the clin-
ical endpoint of engraftment as a proxy measure for hematopoietic
stem and progenitor cell (HSPC) function.
We performed an analysis of BMI and time to engraftment (TTE)
in all patients transplanted at our institution over a two-year interval.
We analyzed data separately from allogeneic bonemarrow recipients
and autologous peripheral blood stem cell recipients. Only data from
the first transplant was analyzed when a subject hadmultiple HSCTs
performed. Linear regression was used to evaluate the relationship
between BMI and TTE. Sixty-one patients had an allogeneic bone
marrow transplant (29 MRD and 32 MURD) and 33 patients had
an autologous HSCT during the study period. There was an inverse
correlation between BMI and TTE in the allogeneic group (r 5
-0.2971, p 5 0.02). BMI did not correlate with TTE in the autolo-
gous HSCT group. BMI also did not correlate with overall survival
in either the autologous or the allogeneic group. Importantly, graft
cell dose did not correlate with TTE in either population.
The negative correlation between BMI and time to engraftment
was unexpected and may be the result of proliferative effects of adi-
pocytes on more mature hematopoietic progenitors. To assess this
possibility in a more controlled setting, we have undertaken an anal-
ysis of HSC and MPP frequency and function by performing mye-
loablative transplants in a murine diet-induced obesity (DIO)
model.STEM CELL BIOLOGY
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TARGETED CLEARANCE OF HUMAN HEMATOPOIETIC STEM CELL NICHES
VIA INHIBITION OF SCF SIGNALING USINGMONOCLONAL ANTIBODY SR-1
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Upon transplantation, hematopoietic stem cells (HSCs) home to
specialized bone marrow niches, self-renew and differentiate and
create new, complete hematolymphoid systems. Unfortunately
HSCT/BMT has been limited in part due the toxic conditioning
regimens, such as irradiation and chemotherapy, deemed necessary
forHSC engraftment.We have previously shown that one important
barrier toHSC engraftment is availability of HSCniche space. In the
absence of pre-transplant conditioning, 99% of HSC niches are oc-
cupied with host HSCs and donor HSC engraftment under these
conditions is minimal. We have shown in mouse models, that elim-
ination of host mouse HSCs using anti-mouse-ckit monoclonal an-
tibody ACK2 allows for 90% donor HSC engraftment with
minimal toxicity in immunodeficient animals, which is sufficient to
cure most hematolymphoid disorders.
We examined the effects of SCF-signaling in human HSCs using
various monoclonal antibodies and verified that anti-human-ckit
monoclonal antibody SR-1 uniquely inhibits SCF binding. We cul-
tured purified human BM HSC and CB HSC (CD341CD38-
CD901CD45RA-Lin-) with SR-1 or 4F7 (a non-active anti-hu-
man-ckit clone) and show that SR-1 uniquely inhibits human HSC
proliferation in vitro. Interestingly, SR-1 did not induce human
HSC cell death via apoptosis, but rather shifted the differentiation
profile and increased Glycophorin A1 and CD411 cells (RBC and
platelets respectively), and decreased output of CD14, CD13, and
CD33 cells (macrophages/myeloid cells).
To examine the depleting capability of SR-1 in vivo, robust hu-
man-mouse hematopoietic chimeras were generated using newborn
NOD/SCID/IL-2Rg null mice IV transplanted with 1000 human
CBHSC post 100cGy. By BM aspirate, average pre-treatment base-
line total human bone marrow engraftment (%hCD45) was 58.6%,
and myeloid chimerism (%hCD13/33) was 25.4%. The mice were
then treated IV with 500ug of SR-1 every other day for 1 week.
Human total and myeloid engraftment 8 weeks post treatment de-
creased by 92.4% and 96.9% respectively, most likely due to deple-
tion of human HSCs that maintain these populations. The
remaining persistent human cells in these animals were primarily
